CIK 0001515673 · Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 272546083
- Phone
- 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-01 | Horn Howard Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +28,160 | 28,160 | ||
| 2025-03-01 | Parschauer Karah Herdman EVP and Chief Legal Officer | Grant or award | +14,494 | 69,690 | ||
| 2025-03-01 | Parschauer Karah Herdman EVP and Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +26,074 | 26,074 | ||
| 2025-02-28 | KAKKIS EMIL D President & CEO | Sale 10b5-1 | −25,000 | $42.48 | $1.1M | 2,158,985 |
| 2025-02-27 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | −2,230 | $42.93 | $96K | 55,751 |
| 2025-02-27 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | −760 | $42.75 | $32K | 54,991 |
| 2024-12-30 | KAKKIS EMIL D President & CEO | Sale 10b5-1 | −11,727 | $42.23 | $495K | 2,183,985 |
| 2024-12-10 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Gift | −648 | 41,840 | ||
| 2024-12-10 | KAKKIS EMIL D President & CEO | Sale 10b5-1 | −8,273 | $50.00 | $414K | 2,195,712 |
| 2024-12-09 | KAKKIS EMIL D President & CEO | Gift 10b5-1 | −20,000 | 2,203,985 | ||
| 2024-10-10 | Horn Howard Chief Financial Officer | Sale | −7,465 | $52.76 | $394K | 92,301 |
| 2024-09-16 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Grant or award | +700 | 42,251 | ||
| 2024-09-03 | KAKKIS EMIL D President & CEO | Sale 10b5-1 | −20,000 | $55.85 | $1.1M | 2,223,985 |
| 2024-09-03 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | −91 | $56.19 | $5K | 41,551 |
| 2024-08-06 | KAKKIS EMIL D President & CEO | Sale 10b5-1 | −20,000 | $50.17 | $1.0M | 2,243,985 |
| 2024-07-02 | Sanders Corazon (Corsee) D. Director | Sale 10b5-1 | −584 | $40.98 | $24K | 12,009 |
| 2024-06-18 | Dunsire Deborah Director | Grant or award | +5,345 | 25,075 | ||
| 2024-06-18 | Dunsire Deborah Director | Grant or award · Stock Option (Right to Buy) | +9,900 | 9,900 | ||
| 2024-06-18 | Fust Matthew K Director | Grant or award | +5,345 | 20,205 | ||
| 2024-06-18 | Fust Matthew K Director | Grant or award · Stock Option (Right to Buy) | +9,900 | 9,900 |
Page 7 of 11 · 204 trades